VolitionRX

VNRX

Medical - Devices · Healthcare

Price

$0.42

-0.03 (-6.19%)

Market Cap

$3.5M

Exchange

New York Stock Exchange Arca

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+102.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.6M (2021) → 5.3M (2025)

Winston Score History

The full picture

VolitionRx is a medical diagnostics company that develops blood tests to help detect cancer and other serious diseases. Its core technology is called "Nu.Q," which measures tiny pieces of DNA called nucleosomes that float in the bloodstream when cells die or become cancerous. The company targets hospitals, clinics, and research institutions, and its tests are designed to work on standard lab equipment already used by most healthcare providers.

VolitionRx makes money by licensing its technology and selling diagnostic test kits to labs and research partners. The company operates primarily in the United States and Europe, with research activities based in Belgium. It is a small, early-stage company that is not yet profitable, as shown by its deeply negative operating margin. The main growth driver is gaining regulatory approvals and clinical adoption for its cancer screening tests, but the key risk is that it continues to burn cash while waiting for those approvals to come through.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-2.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+30.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$10M/ year

↓ Declining (-30% vs prior year)

583.6% of revenue

32.4x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.0%ownership

Relatively low insider ownership

Cash Runway

~2 months

$3M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

VolitionRX has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

0.0%

Thin — 0.0% operating margin

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+86.3%

Fast-growing sales (+86.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-790.4%

Burning cash (-790.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial